Wednesday, March 23, 2011
(worth reading) Editorial: The Values and Value of Patient-Centered Care -- Epstein and Street 9 (2): 100 -- Annals of Family Medicine
"The originators of client-centered and patient-centered health care were well aware of the moral implications of their work, which was based on deep respect for patients as unique living beings, and the obligation to care for them on their terms. Thus, patients are known as persons in context of their own social worlds, listened to, informed, respected, and involved in their care—and their wishes are honored (but not mindlessly enacted) during their health care journey.2–6 There have been concerns that patient-centered care, with its focus on individual needs, might be at odds with an evidence-based approach, which tends to focus on populations. Fortunately, that debate has been laid to rest; proponents of evidence-based medicine now accept that a good outcome must be defined in terms of what is meaningful and valuable to the individual patient.7 Patient-centered care, as does evidence-based medicine, considers both the art of generalizations and the science of particulars.8"
Cochrane Review: abstract - Chemotherapy for malignant germ cell ovarian cancer [Cochrane Database Syst Rev. 2011] - PubMed result
AUTHORS' CONCLUSIONS:
We found only low quality evidence on the use of chemotherapy in malignant germ cell tumours of the ovaries. Therefore we are unable to reach definite conclusions about the relative benefits and harms of chemotherapy use in this disease regardless of disease stage. Due to the benefit of chemotherapy in germ cell cancer of the testis, a trial of chemotherapy versus best supportive care is unlikely to be feasible. Despite this, good quality randomised studies are warranted in this disease to define the role of chemotherapy (type of chemotherapy, duration of treatment, benefit, short and long term toxicities). Given the rarity of this disease, we feel a trans-global approach would be essential in order to perform such trials.
alternate source including professional commentary (gynecologic oncology) link
full free access: (references Dr Folkman 1971) Antiangiogenic Therapies in Epithelial Ovarian Cancer (printer-friendly)
Source: Posted: 03/22/2011; Cancer Control. 2011;18(1):31-43. © 2011 H. Lee Moffitt Cancer Center and Research Institute, Inc.
PLOS Medicine: Promotional Tone in Reviews of Menopausal Hormone Therapy After the Women's Health Initiative: An Analysis of Published Articles
View and Join Ongoing Discussions
Original Article Promotional Tone in Reviews of Menopausal Hormone Therapy After the Women's Health Initiative: An Analysis of Published Articles
| 0 responses | Promotional Tones - Hormone Therapy after WHI | Posted by sandipniauskas on 23 Mar 2011 at 08:32 GMT |
| Most recent response on 23 Mar 2011 at 08:32 GMT | ||
| 2 responses | Pfizer Comment | Posted by cloder on 17 Mar 2011 at 17:54 GMT |
| Most recent response on 22 Mar 2011 at 20:50 GMT | ||
| 1 response | Money isn't enough | Posted by lexchin on 16 Mar 2011 at 16:55 GMT |
| Most recent response on 17 Mar 2011 at 14:27 GMT | ||
| 0 responses | Follow the money... | Posted by EthicalNag on 16 Mar 2011 at 14:40 GMT |
| Most recent response on 16 Mar 2011 at 14:40 GMT | ||
Tuesday, March 22, 2011
Progress Being Made in Genome Sequencing - Medscape interview (in research)
Note: the specific references in this article are colorectal cancer but of interest (re: metastases)
full free access: PROTECT study - Dalteparin versus Unfractionated Heparin in Critically Ill Patients — NEJM (venous thromboembolism-blood clots)
"Venous thromboembolism is an important complication of critical illness.....cont'd
The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group
Methods - Study Design
The trial was conducted in 67 ICUs in academic and community hospitals in Canada, Australia, Brazil, Saudi Arabia, the United States, and the United Kingdom. Recruitment began in May 2006 and, as projected, was completed in 4 years. The trial protocol is available with the full text of this article at NEJM.org.7
abstract: Healthy eating index and ovarian cancer risk - Cancer Causes and Control
Abstract
The evidence for a role of diet on ovarian cancer prevention remains inconclusive. While many studies have evaluated individual foods and food groups, the evaluation of a comprehensive dietary quality index for predicting cancer risk has received little attention. This study investigates the association between the Healthy Eating Index (HEI), which reflects adherence to the current USDA Dietary Guidelines for Americans and ovarian cancer risk in a population-based case–control study in New Jersey. A total of 205 cases and 390 controls completed the Block 98.2 food frequency questionnaire (FFQ) in addition to reporting on potential risk factors for ovarian cancer. FFQ data were then utilized to calculate the HEI score, and cup, ounce, gram, or caloric equivalents for the 12 different food groups comprising the index. In multivariate models, the OR (overall risk) for the highest tertile of the HEI score compared with the lowest (reflecting a better diet compared with a worse diet) was 0.90 (95% CI: 0.55–1.47).
There was limited evidence for a statistically significant association between any of the 12 individual food components and ovarian cancer risk. Based on this study’s results, neither individual food groups nor dietary quality showed potential for preventing ovarian cancer.
There was limited evidence for a statistically significant association between any of the 12 individual food components and ovarian cancer risk. Based on this study’s results, neither individual food groups nor dietary quality showed potential for preventing ovarian cancer.
abstract: Genital powder exposure and the risk of epithelial ovarian cancer Cancer Causes and Control, Online First™
Conclusions
The International Agency for Research on Cancer has designated perineal exposure to talc (via the application of genital powders) as a possible carcinogen in women. A modest association of ovarian cancer with this exposure was seen in our study and in some previous ones, but that association generally has not been consistent within or among studies. Therefore, no stronger adjective than “possible” appears warranted at this time.
Monday, March 21, 2011
What Patients Value When Oncologists Give News of Cancer Recurrence: Commentary on Specific Moments in Audio-Recorded Conversations -- Back et al. 16 (3): 342 -- The Oncologist CME Online
 |
| fig 1 |
Definitions of standardized patient:
A simulated patient or standardized patient (SP) (also known as a patient instructor), in health care, is an individual who is trained to act as a real patient in order to simulate a set of symptoms or problems. ...
en.wikipedia.org/wiki/Standardized_patient
Gastroenterology & Endoscopy News - Is Colonoscopy the Optimal Method for Colorectal Cancer Screening? (no specific mention of Lynch Syndrome
Note: no mention of Lynch Syndrome (biology/genetics), full free access with registration (free)
full free access: Research output on primary care in Australia, Canada, Germany, the Netherlands, the United Kingdom, and the United States: bibliometric analysis - bmj.com
What is already known on this topic
- The UK Research Assessment Exercise in 2008 rated 50% of UK primary care research as world class or internationally excellent, but no direct international comparisons exist
What this study adds
- In six countries with strong primary care, the United Kingdom and the Netherlands produce the most cited primary care led primary care research
- Identifying research on primary care that is carried out by primary care researchers is difficult using routine bibliometric methods
- Only 29% of research papers on primary care had at least one primary care researcher as author
Guest post: Absolute risk not as straightforward as you might think - Gary Schwitzer's HealthNewsReview Blog
"...As a Cochrane review pointed out this week (Persuasive health information could be misleading) (note - this link forwards to a Reuters story) relative risks are very persuasive, but they don't always serve your best interests when making health decisions....:
press release/abstract: Marshall Edwards Announces Publication of Phase II Clinical Trial Results - Phenoxodiol phase 11 ovarian cancer trial results (32 pts)
SAN DIEGO, March 21, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer. The publication is now available on the International Journal of Gynecological Cancer website and scheduled to print in the May issue of the journal......
abstract: Int J Gynecol Cancer. 2011 Mar 15. [Epub ahead of print]
Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers.
Clinical Cancer Research Programs Merge To Accelerate Research
The American College of Radiology's Imaging Network (ACRIN) and the Eastern Cooperative Oncology Group (ECOG), National Cancer Institute (NCI) Clinical Trials Cooperative Group members, have announced their intent to merge their clinical cancer research programs.
The groups plan to form an alliance that combines their complementary strengths. The new organization will include three areas of research emphasis: early detection and diagnosis of cancer; biomarker-driven Phase II and Phase III therapeutic studies for multiple cancer types and stages; and genetic, molecular and imaging marker research to predict and monitor treatment response........cont'd
Limited free speech for docs | Columnists | Comment | Calgary Sun
Comments
Sandi Pniauskas
March 20th 2011, 10:16pm
"I see no mention of the Institute for Patient Safety and their role in these issues. Aside from selected physicians (the few) who choose to speak up publicly, it's rather a continuing sad situation in Canada. For those who do speak up, healthcare professionals, patients and the public, we seem to ostracize those individuals who have the tenacity to persevere in truth telling and simply trying to do the best possible under often terrible circumstances. More so, where is the peer process in this aside from political fence sitting. There is definitely a need for both federal and provincial ombudsman positions 'with teeth'- to correct these ongoing errors of judgment."
Sunday, March 20, 2011
Genetics of Breast and Ovarian Cancer (PDQ®) - NCI - rare syndrome (LFS, Cowden, PJS)
Other Rare Breast and Ovarian Cancer-Associated Syndromes
Li-Fraumeni syndrome
Cowden syndrome
Peutz-Jeghers syndrome
NIH Video Casting Event Summary - Li-Fraumeni Syndrome (LFS) Workshop - 2010 scientists/physicians/families
video meeting/serves as a starting point for the creation of a LFS research consortium.
Author: NIH Office of Rare Disease and the National Cancer Institute
Runtime: 05:31:06
Download: Download Video
How to download a Videocast
CIT File ID: 16253
CIT Live ID: 9741
Permanent link: http://videocast.nih.gov/launch.asp?16253
Commentary MJA Insight: Henry Woo: Abuse of self-pay patient system widespread (ethics)
Note: sound familiar?
(to view subscribe(free)
"....Sadly, the abuse of the self-pay system is widespread in the NSW public hospital system. We may be aware that it is happening, but nothing will change unless patients complain, and this is hardly likely.
Surgeons who aren’t happy with this arrangement appear unwilling to come forward in fear of political retribution, professional isolation and stymied career progression.
If we were to abolish self-pay, would we risk throwing the baby out with the bathwater? We have to balance the risks to our professional standing, our inability to regulate this behaviour and the financial risks to those who can least afford it against the risk of removing patient choice.
I would like to see this practice abolished, but if we cannot speak out about this when it involves unethical behaviour, the balance is heavily tilted against ever eradicating the self-pay system in our public hospitals."
Validation of the Histologic Grading for Ovarian Clear Cell Adenocarcinoma: A Retrospective Multi-institutional Study by the Japan Clear Cell Carcinoma Study Group
Abstract
"Pathologic slides from 150 patients with clear cell adenocarcinoma from the collaborating institutions were reviewed independently by 2 pathologists, and each tumor was graded histologically using the Shimizu-Silverberg and International Federation of Gynecology and Obstetrics (FIGO) grading systems...................... These results suggest that the 2 tested grading systems have limited value for the prognostication of patients with clear cell adenocarcinoma, and that a more effective grading system for this tumor may be required."
Intll Jnl of Oncology: Ganoderma lucidum (herbal mushrooms) exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin (York University Toronto)
"Ganoderma lucidum is a herbal mushroom known to have many health benefits, including the inhibition of tumor cell growth. However, the effect of Ganoderma lucidum on epithelial ovarian cancer (EOC), the most fatal gynecological malignancy, has not yet been reported...................... Taken together, these findings suggest that Ganoderma lucidum exerts multiple anti-tumor effects on ovarian cancer cells and can enhance the sensitivity of EOC cells to cisplatin." |
abstract: Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas
CONCLUSIONS:
OCCCs constitute a heterogeneous disease at the genomic level despite having similar histological features. The pattern of genomic aberrations in subgroups of OCCCs is of clinical significance.
abstract: Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma
Abstract:
ARID1A is a recently identified tumor suppressor gene that is mutated in approximately 50% of ovarian clear cell and 30% of ovarian endometrioid carcinomas. The mutation is associated with loss of protein expression as assessed by immunohistochemistry.
In this study, we evaluated ARID1A immunoreactivity in a wide variety of carcinomas to determine the prevalence of ARID1A inactivation in carcinomas. Mutational analysis of ARID1A was carried out in selected cases. Immunoreactivity was not detected (corresponding to inactivation or mutation of ARID1A) in 36 (3.6%) of 995 tumors.
Uterine low-grade endometrioid carcinomas showed a relatively high-frequency loss of ARID1A expression, as 15 (26%) of 58 cases were negative. The other tumor that had a relatively high-frequency loss of ARID1A expression was gastric carcinoma (11%). Mutational analysis showed 10 (40%) of 25 uterine endometrioid carcinomas; none of 12 uterine serous carcinomas and none of 56 ovarian serous and mucinous carcinomas harbored somatic ARID1A mutations. All mutations in endometrioid carcinomas were nonsense or insertion/deletion mutations, and tumors with ARID1A mutations showed complete loss or clonal loss of ARID1A expression.
In conclusion, this study is the first large-scale analysis of a wide variety of carcinomas showing that uterine low-grade endometrioid carcinoma is the predominant tumor type harboring ARID1A mutations and frequent loss of ARID1A expression. These findings suggest that the molecular pathogenesis of low-grade uterine endometrioid carcinoma is similar to that of ovarian low-grade endometrioid and clear cell carcinoma, tumors that have previously been shown to have a high-frequency loss of expression and mutation of ARID1A.
ARID1A is a recently identified tumor suppressor gene that is mutated in approximately 50% of ovarian clear cell and 30% of ovarian endometrioid carcinomas. The mutation is associated with loss of protein expression as assessed by immunohistochemistry.
In this study, we evaluated ARID1A immunoreactivity in a wide variety of carcinomas to determine the prevalence of ARID1A inactivation in carcinomas. Mutational analysis of ARID1A was carried out in selected cases. Immunoreactivity was not detected (corresponding to inactivation or mutation of ARID1A) in 36 (3.6%) of 995 tumors.
Uterine low-grade endometrioid carcinomas showed a relatively high-frequency loss of ARID1A expression, as 15 (26%) of 58 cases were negative. The other tumor that had a relatively high-frequency loss of ARID1A expression was gastric carcinoma (11%). Mutational analysis showed 10 (40%) of 25 uterine endometrioid carcinomas; none of 12 uterine serous carcinomas and none of 56 ovarian serous and mucinous carcinomas harbored somatic ARID1A mutations. All mutations in endometrioid carcinomas were nonsense or insertion/deletion mutations, and tumors with ARID1A mutations showed complete loss or clonal loss of ARID1A expression.
In conclusion, this study is the first large-scale analysis of a wide variety of carcinomas showing that uterine low-grade endometrioid carcinoma is the predominant tumor type harboring ARID1A mutations and frequent loss of ARID1A expression. These findings suggest that the molecular pathogenesis of low-grade uterine endometrioid carcinoma is similar to that of ovarian low-grade endometrioid and clear cell carcinoma, tumors that have previously been shown to have a high-frequency loss of expression and mutation of ARID1A.
Saturday, March 19, 2011
Ovarian cancer patient ‘failed by consultant’ (The Bolton News) - case of misconduct
Blogger's note: odd that the story didn't mention how the patient is doing ??
"....The panel heard that at a later consultation, the progress of the condition was again not identified and acted on, with poor notes made.
A specialist was not consulted and clinical standards of care were not met...."
abstract: Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome (ethics/informed consent)
From the 1Department of Bioethics, Cleveland Clinic; 2Genomic Medicine Institute Lerner College of Medicine, Cleveland Clinic; and 3Center for Genomic Research Ethics & Law, Case Western Reserve University, Cleveland, Ohio.
Abstract
OBJECTIVE: Routine microsatellite instability (MSI) and immunohistochemistry (IHC) screening of colorectal cancers can assist in identifying a significant proportion of cancers attributable to Lynch syndrome. This article considers whether it is necessary to obtain patient informed consent for microsatellite instability and immunohistochemistry screening.RESULTS: Although microsatellite instability screening examines genetic features of a tumor, it lacks several important characteristics that typically mandate formal informed consent to genetic testing. Microsatellite instability screening describes discrete tissue samples and does not provide information about the rest of the patient's body or germline. In contrast, immunohistochemistry screening is a proteomic test that may reveal information about the patient's germline. As such, immunohistochemistry screening can be viewed as similar to other forms of genetic testing, in which explicit patient consent is regarded as an ethical prerequisite.
CONCLUSION: There is no ethical requirement to obtain explicit informed consent for microsatellite instability screening of colorectal tumor samples for Lynch syndrome. There is support for obtaining patient consent to immunohistochemistry testing, given its similarities with other genetic analyses for which informed consent is typically deemed necessary. Regardless of which screening test is used, it is important to prepare patients and their families for the possibility of a positive screening test.
Friday, March 18, 2011
March 11/2011 Dr Maurie Markman: Prophylactic Oophorectomy and BRCA1/2 Mutations
Note: full free access/requires registration
excerpt:
"Short- and Long-Term Effects of Surgical Menopause
Second, the performance of a bilateral oophorectomy in a premenopausal woman, so-called "surgical menopause," can result in very distressing menopausal symptoms, such as hot flashes, depression, sleep disturbances, vaginal dryness, painful intercourse, etc.[7] It is important to acknowledge that these symptoms are often described as being substantially worse than those experienced following natural menopause. The impact of these symptoms on an individual woman's overall quality-of-life should not be underestimated.Again, the point of noting this concern is not to deny the utility of this surgery in women with a substantial risk of developing ovarian cancer. Rather, it is to be certain that this issue is discussed with the individual woman prior to the performance of the procedure. In this way, she can include this information in her decision-making process....."
OCATS AGM Meeting Regina, Sask - Ovarian Cancer Awareness & Treatment in Saskatchewan (OCATS)
| Time | Saturday, March 19 · 12:00pm - 2:00pm |
|---|---|
OCATS AGM with Judy Wright, Guest Speaker
| Location | Knox Met United Church, Room 105 2340 Victoria Avenue Regina |
|---|---|
| Created By | |
| More Info | Election of Board Members Presentation of financial Statement for 2010 Vote on Change to Bylaws/ARticles/Constituti Guest Speaker: Gifted Counsellor Judy Wright, Judy will share with us a new endeavor of hers, working with clients and horses to help people overcome barriers and physical and emotional pain. Light Lunch by Donation Memberships can be renewed at the door. If you are a paid member, you can vote by proxy, email darlenegray@sasktel.net |
Thursday, March 17, 2011
Drug company (Mylan Pharmaceuticals) recalls pills over dangerous labelling mix-up (Mylan-Minocycline/ Mylan-Amlodipine)
"A pharmaceutical company has launched a voluntary recall of a drug which may have been mislabelled — with possible "life-threatening" consequences for patients with high blood pressure, says Health Canada.
Following a complaint by a pharmacist regarding a prescription product containing the wrong medication, Mylan Pharmaceuticals is recalling one lot of Mylan-Minocycline 50 mg capsules and Mylan-Amlodipine 5 mg tablets, both sold in bottles of 100.
The risk, says Health Canada, is that patients sensitive to tetracyclines or minocycline may be taking minocycline in error, due to mislabelled bottles.
"In addition, a patient who requires MYLAN-AMLODIPINE for their high blood pressure or angina will not get the medication needed to help them treat these conditions," said a Health Canada statement.
Mylan-Amlodipine is used to treat high blood pressure and chest pains. Mylan-Minocycline is used to treat certain types of skin infections, urinary tract infections, gallbladder infections, and respiratory tract infections such as bronchitis, pneumonia, and sinusitis.
WHO | World Health Organization - radiation information/FAQ
WHO warns against self-medicating against radiation
17 March 2011 -- WHO is cautioning people concerned about the radiation issues in Japan against self-medicating with potassium iodide or taking products containing iodine. The advice follows reports of people using these substances in response to radiation leaks from nuclear plants in Japan. Potassium iodide should only be taken when there is a clear public health recommendation to do so.
journal index: Surgical Clinics of North America - Current Issue surgical palliative care papers
full free access: PLoS ONE: Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis (Mar 15/2011)
Note: research/technical/primary focus on serous cell type
abstract: Low-grade serous primary peritoneal carcinoma
Objective
10% of women with serous ovarian cancer have low-grade carcinomas. These patients are diagnosed at a younger age, have a longer overall survival and a lower response rate to platinum-based chemotherapy compared to women with high-grade serous ovarian carcinoma. It remains unclear if these features are similar in women with low-grade primary peritoneal cancer (PPC). To further explore this issue, a retrospective analysis of the clinical and pathologic characteristics of women with low-grade serous PPC was performed.Conclusion
To our knowledge, this is the first report of women with low-grade serous PPC. Similar to low-grade serous ovarian carcinoma, patients with low-grade serous PPC have high rates of persistent disease at the completion of primary treatment yet a long overall survival. Further study focusing specifically on low-grade serous ovarian and primary peritoneal carcinomas is needed to determine the optimal treatment of these diseases.Research Highlights
► This study is the first reported series of women with low-grade serous primary peritoneal cancer.► The pathogenesis and clinical behavior of low-grade serous ovarian and primary peritoneal are distinct from high-grade serous tumors.
► Women with low-grade primary peritoneal cancer have high rates of persistent disease at the completion of primary treatment, yet have a prolonged survival.
Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
Abstract
Objective
To compare survival of ovarian cancer patients treated with neoadjuvant chemotherapy followed by intraperitoneal (IP) versus intravenous (IV) chemotherapy after optimal interval debulking.Conclusions
Survival benefit associated with IP chemotherapy after optimal upfront surgery may not translate to the neoadjuvant setting.Radical fimbriectomy: A reasonable temporary risk-reducing surgery for selected women with a germ line mutation of 1 or 2 genes? Rationale and preliminary development
index: Gynecologic Oncology V121 Issue1 April 2011
Wednesday, March 16, 2011
Alberta health board CEO lobbies doctors for patients' help
"....But more doctors are coming forward to discuss how the system hasn't let them speak freely because they face intimidation and punishment, says Independent legislative member Raj Sherman......."cont'd
Read more: http://www.edmontonjournal.com/Alberta+health+board+lobbies+doctors+patients+help/4452643/story.html#ixzz1GoiC9B2m
Tuesday, March 15, 2011
Doctors 2.0 conference Paris 2011 - Speakers (includes Gilles Frydman/ACOR)
Speakers include:
Gilles Frydman is the head of ACOR, the Association of Cancer Online Resources, founded in 1995 in New York, and the largest online cancer patient community with 65 000 patients and caregivers. ACOR’s 159 electronic lists deliver approximately 1.5 million email messages weekly. The ACOR community has demonstrated its ability to accelerate the distribution of quality information regarding trials, treatments, pharmacovigilance.
Acta Oncologica - summary - Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovaria
Discussion. FDG uptake (SUVmax) in the primary tumor of patients with advanced ovarian cancer was not a prognostic variable and the FDG uptake did not predict complete cytoreduction after primary surgery. Future prospective clinical trials will need to clarify if other PET tracers can serve as prognostic variables in ovarian cancer.
Monday, March 14, 2011
Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure Practices -- American Journal of Public Health selected articles
Note: this journal is by subscription ($$$)
AJPH First Look, published online ahead of print Jan 13, 2011
© 2011 American Public Health Association
DOI: 10.2105/AJPH.2010.300027
GOVERNMENT, POLITICS, AND LAW |
Sheila M. Rothman is with the Division of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY, and the Center for the Study of Society and Medicine,
College of Physicians and Surgeons, Columbia University. Victoria H. Raveis is with the Psychosocial Unit on Health, Ageing, and Community, New York University College of Dentistry, New
York. At the time of the study Anne Friedman was with the Center on Medicine as a Profession, College of Physicians and Surgeons, Columbia University. David J. Rothman is with the College
of Physicians and Surgeons, Columbia University.
Correspondence: Correspondence should be sent to Sheila M. Rothman, Center for the Study of Society and Medicine, College of Physicians and Surgeons, Columbia University,
630 West 168th St, PH 15-25, New York, NY 10032 (e-mail: smr4@columbia.edu). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints/Eprints" button.
Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's
marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed.
We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns.
Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor.
No HAO disclosed the exact amount of a Lilly grant.
As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators,
and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.
This article has been cited by other articles:
 | |  | |   M. Weinberg Patient Advocacy Organizations and Corporate Relationships Am J Public Health, April 1, 2011; 101(4): 582 - 583. [Full Text] [PDF] | |
eLetters:
Read all eLetters- Health Advocacy Organizations: Transparency is important and so is evidence
- Frances M Visco
- AJPH Online, 17 Jan 2011 [Full text]
- Patient Advocacy Organizations are Committed to Transparency
- Myrl Weinberg
- AJPH Online, 20 Jan 2011 [Full text]
- Re: Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis
- Jack Harris, et al.
- AJPH Online, 24 Jan 2011 [Full text]
abstract: Patient Advocacy Organizations and Corporate Relationships -- Weinberg 101 (4): 582 -- American Journal of Public Health
April 2011, Vol 101, No. 4 | American Journal of Public Health 582-583
© 2011 American Public Health Association
DOI: 10.2105/AJPH.2011.300087
LETTERS |
Myrl Weinberg is president of the National Health Council, Washington, DC.
Correspondence: Correspondence should be sent to Myrl Weinberg, National Health Council, 1730 M Street, NW, Suite 500, Washington, DC 20036-4561 (e-mail: mweinberg@nhcouncil.org). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints/Eprints" link.
| |||
|
| | |
| |||
The NHC agrees with Rothman et al. about the need for transparency.1 For this reason, any patient advocacy organization that wishes to join or retain its membership in the NHC must disclose funding received from corporations and present the information in an easily accessible manner within 6 months of the close
(NCCN) Updated Ovarian Cancer Guidelines Offer a New Treatment Choice
Note: this refers to the Japanese study published 2010 of weekly Taxol - search blog for the original study and additional commentaries
March 14, 2011 — The updated 2011 National Comprehensive Cancer Network (NCCN) Ovarian Cancer Guidelines have added a new treatment option — dose-dense paclitaxel — for the first-line treatment of stage II, III, or IV epithelial ovarian cancer.
The category 1 recommendation comes from data from the Japanese Gynecologic Oncology Group, said panel chair Robert J. Morgan, MD, professor of medicine at the City of Hope Comprehensive Cancer Center in Duarte, California, here at the NCCN 16th Annual Conference.
In a phase 3 open-label randomized controlled trial published in the Lancet (2009; 374:1331-1338), Noriyuki Katsumata and colleagues reported that dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer resulted in a significant survival advantage. The study concluded that paclitaxel and carboplatin given every 3 weeks is standard treatment for advanced ovarian carcinoma.
"This was an important addition," Dr. Morgan told Medscape Medical News........"
PharmaLive: Topotarget Announces Updates on Belinostat in Two Clinical Trials - NSCLC and Ovarian Cancer (negative study ovarian/Belinostat/Carboplatin)
Ovarian cancer – GOG 0126-T (NCI-driven study)
Preliminary analysis of GOG 0126-T trial has not shown enough activity to enter into second stage. Consequently the study will be ended.
The study
The study is an open-label single-arm phase II trial with belinostat in combination with carboplatin given to patients with ovarian cancer who progress during or shortly after first-line treatment with platinum containing chemotherapy. The trial is sponsored by the GOG with support from the NCI. Belinostat is administered as a 30-minute daily IV infusion on day one through five with carboplatin being administered on day three. Treatment is given every third week and is repeated until disease progression......
Subscribe to:
Posts
(
Atom
)
